Biomarin Pharmaceutical Inc. (NASDAQ:BMRN) saw an upside of 1.17% to close Tuesday at $88.06 after adding $1.02 on the day. The 5-day average trading volume is 1,279,440 shares of the company’s common stock. It has gained $89.66 in the past week and touched a new high 1 time within the past 5 days. An average of 1,176,470 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 1,127,980.
BMRN’s 1-month performance is -5.96% or -$5.58 on its low of $85.76 reached on 09/22/23. The company’s shares have touched a 52-week low of $80.53 and high of $117.77, with the stock’s rally to the 52-week high happening on 01/27/23. YTD, BMRN has lost -14.91% or -$15.43 and has reached a new high 12 times. However, the current price is down -25.23% from the 52-week high price.
Insider Transactions
BMRN stock investors last saw insider trading activity on Aug 16.Ajer Jeffrey Robert (EVP, Chief Commercial Officer) most recently sold 5,000 shares at $90.00 per share on Aug 16. This transaction cost the insider $450,000. President, Worldwide R&D, FUCHS HENRY J, sold 12,000 shares at a price of $90.43 on Aug 10. Then, on Aug 09, EVP, Chief Technical Officer Guyer Charles Greg sold 5,360 shares at a price of $93.30 per share. This transaction amounted to $500,109.
Valuation Metrics
BMRN stock has a beta of 0.37. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 7.56 while the price-to-book (PB) in the most recent quarter is 3.46, with the price to cash flow ratio at 330.04.
Biomarin Pharmaceutical Inc.’s quick ratio for the period ended June 29 was 3.31, with the current ratio over the same period at 4.94. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.23, while the total debt to equity was 0.23.. In terms of profitability, the gross margin trailing 12 months is 74.42%. The trailing 12-month EBITDA margin is 5.48% while for the period ending June 29, Biomarin Pharmaceutical Inc.’s operating margin was 3.22%. The firm’s gross profit as reported stood at $1.61 billion against revenue of $2.1 billion.
Earnings Surprise
For the quarterly period ending June 29 this year, Net income and sales went down compared to those figures reported in the previous quarter. Net income grew 50.64% to $56.04 million, while revenue of $50.85 million was 9.26% off the previous quarter. Analysts expected BMRN to announce $0.23 per share in earnings in its latest quarter, but it posted $0.29, representing a 26.10% surprise. EBITDA for the quarter stood at more than $81.73 million. BMRN stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 1.78 billion, with total debt at $1.09 billion. Shareholders hold equity totaling $188.18 million.
Let’s look briefly at Biomarin Pharmaceutical Inc. (BMRN) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 26 September was 44.27% to suggest the stock is trending Neutral, with historical volatility in this time period at 26.78%.
The stock’s 5-day moving average is $87.25, reflecting a -0.86% or -$0.76 change from its current price. BMRN is currently trading -6.00% above its 20-day SMA, -5.90% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by +1.60% and SMA200 by-15.07%.
Stochastic %K and %D was 20.07% and 13.11% and the average true range (ATR) pointed at 1.83. The RSI (14) points at 44.65%, while the 14-day stochastic is at 31.99% with the period’s ATR at 1.87. The stock’s 9-day MACD Oscillator is pointing at -0.52 and -1.70 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Biomarin Pharmaceutical Inc. (NASDAQ: BMRN), UBS launched coverage with a Buy rating. Analysts offering their rating for BMRN stock have a consensus rating for the stock as Overweight. Currently, 0 brokerage advisors rate BMRN as a “sell,”, while 8 advise that investors “Hold.” 1 analysts have rated the stock as underweight. 3 rates the stock as overweight while 15 have offered a “buy” rating.
What is BMRN’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $78.00 and a high of $185.00, with their median price target at $112.00. Looking at these predictions, the average price target given by analysts is for Biomarin Pharmaceutical Inc. (BMRN) stock is $116.87.
